Tasly Pharmaceutical Group Co. Ltd. Class ASSE: 600535

"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Subsidiary Obtaining the Notice of Approval for Clinical Trial

Aug 22, 2026 · Issued by Tasly Pharmaceutical Group Co. Ltd. Class A via Shanghai Stock Exchange

Announcement on Subsidiary Obtaining the Notice of Approval for Clinical Trial

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Tasly Pharmaceutical Group Co. Ltd. Class A

"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Amendments to the Articles of AssociationAug 11
"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on a Wholly-owned Subsidiary's Receipt of Clinical Trial Notice for the Extension of the Treatment Time Window for the Acute Ischemic Stroke Indication of Recombinant Human Pro-urokinase for InjectionJul 18
"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Semi-annual Performance for 2026Jul 15
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026Jun 26

All Tasly Pharmaceutical Group Co. Ltd. Class A news releases